Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: A meta-analysis of the randomized placebo-controlled trials

Archives of Internal Medicine

Volumn 156, Issue 3, 1996, Pages 259-264

  Johnson, Jennal L ^a   Wolf, Susan L ^a   Kabadi, Udaya M ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; INSULIN; SULFONYLUREA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; MAJOR CLINICAL STUDY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; RANDOMIZED CONTROLLED TRIALS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 0030065192     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.3.259     Document Type: Article

References (61)

1. Screening diabetes: Position statement by American Diabetes Association. Diabetes Care. 1995;18(suppl).5-7.
2. Rifkin H, ed. The Physician's Guide to Type II Diabetes (NIDDM): Diagnosis and Treatment. Alexandria, Va: American Diabetes Association, 1985,1-112.
3. Zavaroni I, Bonora E, Pagliara M, et al Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance N Engl J Med. 1989,320.702-706.
4. Stout RW. Insulin and atheroma Diabetes Care. 1990,13.631-654
5. Riddle M, Hart JS, Bouma DJ, Phillipson BE, Youker G. Efficacy of bedtime NPH insulin in treatment of secondary failure to glyburide. Diabetes Care 1989,12:582-585.
6. Trischitta V, Italia S, Borzi V, et al. Low-dose bedtime NPH insulin in treatment of secondary failure to glyburide. Diabetes Care. 1989;12:582-585.
7. Riddle M, Hart J, Bouma D, Phillipson B, Youker G. An effective new regimen for type II diabetes: bedtime insulin with daytime sulfonylurea. Diabetes 1986, 35(suppl):263. Abstract.
8. Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure. Diabete Metab. 1991,17:218-223.
9. Fabrykant M. Favorable effects of supplemental Orinase in insulin treated labile diabetes Metabolism. 1957;6:509-517
10. Fabrykant M. Use of Orinase as a basic adjuvant in management of insulin-dependent diabetes Metabolism 1958;7:213-221
11. Fabrykant M, Ashe B. Combined insulin-tolbutamide therapy in the management of insulin-dependent diabetes. Ann N Y Acad Sci 1959:82:585-589
12. Volk B, Lazarus S Significance of effectiveness of combined insulin-orinase treatment in maturity-onset diabetes Am J Med Sci. 1959;237:1-7.
13. Bernard H Long-term observations on oral hypoglycemic agents in diabetes the effect of carbutamide and tolbutamide. Diabetes. 1965,14:59-70.
14. Otto H, Otto-Bendfeldt E. Use of combined treatment with insulin and sulfonylurea compounds in diabetes mellitus Indian J Med Sci. 1967;21.221-228.
15. Groop L, Harno K, Nousianinen R, Karonen S. The combination of insulin with sulfonylurea in the treatment of maturity-onset diabetes Acta Endocrinol. 1980,227 28-29.
16. Hamelbeck H, Klein W, Zoltobrocki M, Schoffling K. Glibenclamide-insulin-Kombinations behandlung beim Sekundarversagen der Sulfonylharnstoff-Terapie Dtsch Med Wochenschr. 1982,107:1581-1583.
17. Groop L, Harno K, Tolppanen E. The combination of insulin and sulfonylurea in the treatment of secondary drug failure in patients with type II diabetes. Acta Endocrinol. 1984;106:97-101.
18. Bieger W, Dlugosch R, Rettenmeier A, et al. Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Klin Wochenschr. 1984;62:631-639.
19. Osei K, O'Dorisio T, Falko J. Concomitant insulin and sulfonylurea therapy in patients with type II diabetes: effects on glucoregulation and lipid metabolism. Am J Med. 1984;77:1002-1008
20. Groop L, Harno K, Mikkila E, Pelkonen R, Tolppanen E. Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin-dependent diabetics poorly controlled with insulin alone. Acta Med Scand 1985;217:33-39.
21. Kyllastinen M, Groop L Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. Ann Clin Res. 1985;17 100-104.
22. Ladinosis C, Liu G, Reaven G. Glyburide in non-insulin-dependent diabetes Arch Intern Med. 1985,145:1028-1032.
23. Allen BT, Feinglos MN, Lebovitz HE. Treatment of poorly regulated non-insulin-dependent diabetes mellitus with combination insulin-sulfonylurea. Arch Intern Med. 1985;145:1900-1903.
24. Allen B, Feinglos M. Persistent effect of sulfonylurea therapy in patients with 'secondary failure' Diabetes. 1985,34(suppl):112A. Abstract No. 443.
25. Longnecker M, Elsenhans V, Leiman S, Owen O, Boden G. Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus. Arch Intern Med 1986;146.673-676
26. Mauerhoff T, Ketelslegers J, Lambert A. Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion. Diabete Metab. 1986;12 34-38
27. Quatrato A, Consoli G, Ceriello A, Giugliano D Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Diabete Metab 1986;12:315-318.
28. Falko J, Osei K. Concentration insulin/glyburide therapy in type II diabetes mellitus. Am J Med. 1995.79:92-101.
29. Simonson DC Delprato S, Castellino P, Groop L, De Fronzo R. Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients Diabetes. 1987;36.136-146.
30. Shade D, Mitchell W, Griego G. Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes JAMA. 1987,257:2441-2445
31. Reich A, Abraira C, Lawrence A. Combined glyburide and insulin therapy in type II diabetes. Diabetes Res. 1987;6:99-104
32. Kitabchi A, Soria A, Radparvar A. Lawson-Grant V Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with non-insulin-dependent diabetes mellitus. Am J Med Sci. 1987;294:10-14
33. Schwartz S, Fischer J, Kipnes M, Boyle M Effects of short-term insulin therapy upon therapeutic response to glipizide. Am J Med 1987,83(suppl 3A).22-30.
34. Gutniak M, Karlander SG, Efendic S. Glyburide decreases insulin requirement, increases B-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care. 1987;10:545-554.
35. Holman R, Steemson J, Turner R. Sulfonylurea failure in type II diabetes: treatment with a basal insulin supplement. Diabet Med. 1987;4:457-462.
36. Castillo M, Scheen AJ, Paolisso G, Lefebvre PJ The addition of glipizide to insulin therapy in type II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol. 1987;116:364-372
37. Lins P, Lundblad S, Persson-Trotzig E, Adamson U. Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy Acta Med Scand. 1988;223:171-179.
38. Stenman S, Groop P-H, Saloranta C, Totterman KJ, Fyhrquist F, Groop L Effects of the combination of insulin and glibenclamide in type II (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycemic agents. Diabetologia. 1988;31:206-213
39. Casner P. Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial. Clin Pharmacol Ther 1988;44:594-603.
40. Mezitis N, Heshka S, Saitas V, et al. Combination therapy for diabetes mellitus (DM) type II with biosynthetic human insulin and glyburide. Diabetes 1988; 25(suppl)99 Abstract
41. Sontaniemi E. Insulin and sulfonylurea in the therapy of type 2 diabetes. Diabetes Res Clin Pract. 1990;8:243-251.
42. Lewitt M, Yu VCF, Rennie GC, et al Effects of combined insulin-sulfonylurea therapy in type II patients Diabetes Care 1989;12:379-383.
43. Simpson H, Sturley R, Stirling C, Reckless J. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients. Diabet Med. 1990,7:143-147.
44. Groop P, Stenman S, Totterman K, Fyhrquist F. Combination of insulin and glibenclamide in the treatment of secondary drug failure in NIDDM. Diabetes 1986,35(suppl):260. Abstract.
45. Mohan V, Snehalatha C, Ramachandran A, Viswanathan M. Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs. J Assoc Phys India 1990;38:537-541
46. Mezitis N, Heshka S, Saitas V, Bailey TS, Costa R, Pi-Sunyer FX. Combination therapy for NIDDM with biosynthetic human insulin and glyburide. Diabetes Care 1992;15.265-269.
47. Pasmantier R, Chaiken R, Hirsch S, Lebovitz H. Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM. Diabetes Care 1990. (suppl 3):42-46.
48. Pontiroli A, Dino G, Capra F, Pozza G. Combined therapy with glibenclamide and Ultralente insulin in lean patients with NIDDM with secondary failure of sulfonylureas: follow-up at two years. Diabete Metab. 1990;16:323-327.
49. Liu D, Wettergren M, Lins P, Adamson U Combined insulin-glibenclamide therapy of NIDDM patients in primary health care Scand J Prim Health Care 1990;8 213-217.
50. Klein W. Sulfonylurea-metformin combination vs sulfonylurea-insulin combination in secondary failure of sulfonylurea monotherapy. Diabete Metab. 1991;17.235-240
51. Kabadi U, Kabadi M. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed Ultralente and regular insulin with a sulfonylurea J Fam Pract 1991;33:349-353
52. Del Prato S, Vigili de Kreutzenberg S, Riccio A, et al. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents Diabetologia 1990,33:688-695.
53. Peters A, Davidson M. Insulin plus a sulfonylurea agent for treating type 2 diabetes Ann Intern Med. 1991;114.45-53.
54. Pugh J, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? Diabetes Care. 1992,15:853-959.
55. Hedges LV, Olkin I Statistical Methods for Meta-analysis. Orlando, Fla: Academic Press Inc; 1985:305-306.
56. Moody L. Meta-analysis: qualitative and quantitative methods In: Moody L, ed. Advancing Nursing Science Through Research. Thousand Oaks, Calif Sage Publishers; 1990,2.70-107
57. Vigneri R, Trischitta V, Italia S, Mazzarino S, Rabuazzo MA Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. Diabete Metab. 1991;17:232-234
58. Yki-Jarvinen H, Kauppila M, Kujansuue E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327 1426-1433
59. Melander A. Clinical pharmacology of sulfonylurea Metabolism. 1987;36:12-16
60. Cohen KL, Harris S Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemics. Diabetes Care. 1987;10:555-557
61. Kumar S. Current management strategies in diabetes [proceedings issue]. Endocrinol Metab. 1993:A53-A55.